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Abstract 
Background: Anti-malarial resistance is, and continues to be a significant challenge in the fight against malaria and 
a threat to achieving malaria elimination. In Zambia, chloroquine (CQ), a safe, a!ordable and well-tolerated drug, was 
removed from use in 2003 due to high levels of resistance evidenced with treatment failure. This study sought to 
investigate the prevalence of chloroquine resistance markers in Southern and Western Provinces of Zambia 14 years 
after the withdrawal of CQ.
Methods: Data from a cross-sectional, all-age household survey, conducted during the peak malaria transmission 
season (April–May 2017) was analysed. During the all-age survey, socio-demographic information and coverage of 
malaria interventions were collected. Consenting individuals were tested for malaria with a rapid diagnostic test and 
a spot of blood collected on filter paper to create a dried blood spot (DBS). Photo-induced electronic transfer–poly-
merase chain reaction (PET–PCR) was used to analyse the DBS for the presence of all four malaria species. Plasmodium 
falciparum positive samples were analysed by high resolution melt (HRM) PCR to detect the presence of genotypic 
markers of drug resistance in the P. falciparum chloroquine resistance transporter (Pfcrt) and P. falciparum multi-drug 
resistance (Pfmdr) genes.
Results: A total of 181 P. falciparum positive samples were examined for pfcrt K76T and MDR N86. Of the 181 samples 
155 successfully amplified for Pfcrt and 145 for Pfmdr N86. The overall prevalence of CQ drug-resistant parasites was 
1.9% (3/155), with no significant di!erence between the two provinces. No N86Y/F mutations in the Pfmdr gene were 
observed in any of the sample.
Conclusion: This study reveals the return of CQ sensitive parasites in Southern and Western Provinces of Zambia 
14 years after its withdrawal. Surveillance of molecular resistant markers for anti-malarials should be included in the 
Malaria Elimination Programme so that resistance is monitored country wide.
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Background
!e goal of the Zambia National Malaria Elimination 
Programme is to eliminate malaria by 2021, through 
e"ective and sustained coverage of proven vector con-
trol interventions, which include indoor residual spraying 
(IRS), distribution of long-lasting insecticide-treated nets 
(LLINs) and larval source management (LSM), combined 
with prompt e"ective case management, health promo-
tion, surveillance and research [1]. While the malaria 
map has been shrinking over the years, there are a num-
ber of challenges in maintaining control or progressing to 
elimination, that include: access to treatment for most at 
risk and hard to reach populations; insecticide resistance; 
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specifically the threat of resistance to artemisinin and 
artemisinin-based combination therapy [2].
Anti-malarial drug resistance is defined as the ability 
of Plasmodium parasite strain to survive and/or multi-
ply despite the administration and absorption of a drug 
in a dose equal to or higher than the recommended dose, 
but within tolerance of the human subject [3]. Resist-
ance to chloroquine (CQ) in P. falciparum parasites is 
predominantly linked to a single mutation in the P. falci-
parum transporter gene (Pfcrt) on chromosome 7, which 
encodes a protein localized on the parasite digestive 
vacuole (DV) membrane. !e replacement of lysine (K) 
at position 76 to a threonine (T), i.e. the K76T mutation, 
has been established as the most important prognostic 
marker of treatment failure [4, 5].
CQ acts against the intra-erythrocytic (trophozoite and 
schizont) stages of the parasite that are responsible for 
the clinical manifestation of the disease. !e intra-eryth-
rocytic stages digest erythrocytic haemoglobin in acidic 
vacuoles, releasing toxic haem as a by-product which is 
then biocrystallized into non-toxic haemozoin [6]. CQ 
interrupts this detoxification process [7], thus poisoning 
the parasite [8]. CQ resistant (CQR) P. falciparum para-
sites survive by reducing the accumulation of CQ in the 
food digestive vacuole thus inhibiting haemozoin forma-
tion [6, 9].
Another point mutation N86Y in P. falciparum multi-
drug resistance gene 1 (Pfmdr1), on chromosome 5, that 
encodes a P-glycoprotein homologue and is located on 
the parasite DV membrane has also been implicated in 
CQ resistance [4, 5]. !e exact mechanism by which this 
is achieved remains unknown, it is likely mediated by an 
ATP dependent transporter [9].
However, the mutation in Pfcrt is required to confer a 
basic level of resistance before mutations in Pfmdr1 can 
have an e"ect [10].
CQ was introduced in 1940 and by 1950 it had become 
the most widely used anti-malarial. It was the mainstay 
for presumptive treatment and mass drug administration 
during the era of malaria eradication campaigns; while in 
tropical Africa where there was no systematic campaign 
it e"ectively replaced quinine in the 1970s [11, 12]. From 
the early 1980s, there had been observed decreases in CQ 
e#cacy, and increased number of clinical recrudescence 
and treatment failures [13–16]. !erapeutic e#cacy 
studies in Zambia [17] and other neighbouring countries 
[12] also provided evidence for the resistance. !is led to 
Zambia becoming the first African country to abandon 
CQ and adopt artemether–lumefantrine (AL) as the first-
line treatment nationwide in 2002 [18].
Over the years following the withdrawal of CQ, a num-
ber of countries, e.g. China in 2017 [19], Malawi in 2014 
[20] and parts of Zambia in 2016 [21] have reported the 
return of CQ susceptibility, potentially raising the pros-
pect of its reintroduction in the future. !is study, there-
fore, aimed to assess the status of CQ resistance marker 
in Western and Southern Provinces, Zambia to deter-
mine whether CQ sensitivity has continued to return.
Methods
Study area
Western and Southern Provinces cover areas of approxi-
mately 126,000$ km2 and 86,000$ km2, respectively, rep-
resenting ~ 28% of the total Zambia landmass. !ey are 
home to approximately 0.9 and (Western) 1.6 (Southern) 
million people according to the 2010 population census. 
!e Zambezi River flows through both provinces and the 
plains cover an area of about 10% of the total area of the 
Western Province. !e predominant ethnic groups are 
the Tonga speaking people in Southern Province and the 
Lozi speaking people in Western Province [22, 23].
Study design
!is study aimed to assess the levels of CQ resistance in 
selected parts of Western and Southern Provinces using 
samples taken from an all age household cross-sectional 
survey. !e survey was conducted in the two Provinces 
of Zambia during the peak malaria transmission season 
in April and May 2017. !e Ministry of Health, PATH-
Malaria Control and Elimination Partnership in Africa 
(MACEPA), and other partners carried out this survey as 
part of the ongoing e"orts to evaluate malaria elimination 
e"orts. From the survey, a subset of known malaria test 
RDT positive samples were analysed for Pfcrt and Pfmdr 
markers. In the two provinces sampled, malaria transmis-
sion varies greatly, with traditionally higher transmission 
intensity in Southern Province along Lake Kariba and in 
areas of Western Province around the swamps and wet-
land in Luampa, Kaoma and Nkeyema districts and along 
the Zambezi River basin [24–26]. !e rest of the areas 
away from water bodies generally have low transmission.
Selected households were visited by field teams con-
sisting of trained survey data collectors using standard-
ized questionnaires based on the 2015 Malaria Indicator 
Survey (MIS) questionnaire to collect socio-demographic 
characteristics of household members and informa-
tion on coverage of malaria interventions. In addition, 
malaria testing using malaria rapid diagnostic tests (SD 
Bioline Pf ) was done on household members of all ages 
and dried blood spots were collected on Whatmann No 3 
filter paper. Informed consent/assent was obtained from 
the participants that were included in the study [26, 27]. 
Samples were analysed at the National Malaria Elimina-
tion Centre (NMEC) Laboratory.
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Sampling
!e survey sampling methods in each province were dif-
ferent due to historical studies and enumeration in the 
two provinces. In Southern Province, sampling of house-
holds was done randomly based on a pre-existing sam-
pling frame used during a previously-implemented mass 
drug administration (MDA) trial from the 10 districts 
along Lake Kariba. !is involved the random selection of 
52 households from each of the 60 health facility catch-
ment areas used during the trial [25]. For Western Prov-
ince, with no pre-existing household sampling frame, a 
2-stage cluster sampling method using probability pro-
portional to their size (PPS) was employed. Using stand-
ardized methods from the MIS and national census data 
[25, 26], 25 households were selected from 24 standard 
enumeration areas. Across both surveys, a total sam-
ple size of 6977 people was attained. For this study, after 
excluding clusters with zero prevalence, 13 clusters were 
randomly selected and all the1567 (22% of total sam-
ples collected in the 13 clusters) samples screened for 
Plasmodium species by PET–PCR. A total of 266/1567 
(16.9%) were P. falciparum positive. Due to cost of pro-
cessing, 181 of these positives were randomly selected for 
the presence of Pfcrt K76T and Pfmdr N86Y/F.
Laboratory methods
DNA extraction
DNA was extracted either individually or in pools using 
Qiagen DNA mini kit (Qiagen, Germany) using a 6$mm 
punch (~ 13.8$ µl whole blood) taken from each DBS 
according to the manufacturer’s instructions with modi-
fications. All RDT positive samples were extracted indi-
vidually, while RDT negatives were pooled in groups of 
10 and the positive pools were deconvoluted.
PET–PCR
!is was performed as previously described by Luc-
chi et$al. in 2013 [28]. Briefly, 5$µl of DNA template, 2X 
TaqMan Environmental Master Mix 2.0 (Applied BioSys-
tems, Life Technology LTD, Warrington, UK) and 250$nM 
each forward and reverse primers were amplified in a 
20$µl reaction volume as follows; initial hot-start at 95$°C 
for 15$min, followed by 45 cycles of denaturation at 95$°C 
for 20$s, annealing and extension at 60$ °C for 40$s. Sam-
ples were tested in duplicate and scored positive if both 
duplicates had a critical threshold (CT) value < 40 [29, 30].
Pre-ampli!cation
Plasmodium falciparum positive samples were pre-
amplified using a Pre-amplification master mix (Life 
Technologies, Inc, Grand Island, NY, USA) and a mix-
ture of the pooled primers in a 10$ µl (CT > 35) or 20$ µl 
(CT < 35) reaction volume to enhance the template 
concentration. !e following amplification conditions 
were used: pre-incubation at 95$ °C for 2$min, amplifica-
tion at 95$°C for 15$s and 60$°C for 4$min and final exten-
sion 60$°C for 15$s.
Parasite genotyping
pfcrt$K76T and pfmdr N86Y mutations were assessed as 
described previously with minor modifications [31, 32]. 
Briefly, samples were prepared in a 5$µl reaction volume 
consisting of 2µl Lightscanner Master Mix (BioFire Diag-
nostics, Salt city,$ UT, U.S.A), 2.5 µl pre-amplified tem-
plate, and 0.5 µl of primers and probes. !e primers were 
in an asymmetric forward to reverse ratio of 1:5 (0.5$µM 
forward excess primer-, 0.1$ µM reverse limiting primer, 
and 0.4$ µM of the mismatched oligonucleotide at the 
end as a probe), and then amplified as follows amplifica-
tion conditions$95$°C denaturation for 2$min, 50 cycles of 
94$°C for 5$s and 66$°C for 30$s, and a pre-melt cycle of 5$s 
each at 95$°C and 37$°C. !e change in fluorescence was 
recorded over a temperature range from 40$°C to 90°C on 
the Light Cycler 480 system (Roche Diagnostics, Applied 
Science, Germany) and analysed using the Call-It module 
within the Light Cycler software.
Statistical analysis
Demographic and laboratory data of participants records 
were analysed using Stata version 13 (College Station, 
Texas, USA).
Ethical clearance
Ethical clearance was obtained from the Regional Com-
mittee for Medical and Health Research Ethics (REC 
Western Norway) Ref no. 2016/1393/REK Vest and from 
the University of Zambia Biomedical Research Ethics 
Committee (UNZABREC) Ref no. 010-05-16. As this 
analysis was part of a larger study, ethical clearance for 
the larger study was also obtained from UNZABREC 
Ref no. 007-03-14. Permission to use data was obtained 
from the Ministry of Health. All data analysed were 
anonymized.
Results
Of the 181 samples, 155 (85.6%) were successfully ampli-
fied. Table$ 1 shows the demographic characteristics of 
the study participants associated with these samples. 
!ere were 72 (46.5%) males and 83 (53.5%) females and 
the mean age was 20.8$years with a range from 1$year to 
93$years.
Prevalence of!Pfcrt K76T and!Pfmdr N86Y
For Pfcrt, only 1 (0.6% 95% CI 0.02, 3.5) of the sam-
ples had the resistant allele with 2 (1.3% 95% CI 0.2, 
4.6) samples having both resistant and sensitive alleles. 
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Resistance, described, in this paper, as any sample con-
taining a resistant alleles, was found in 3 samples [1.9% 
(95% CI 0.4, 0.6)]. For Pfmdr N86Y/F, all the 145 (100%) 
samples that successfully amplified had the sensitive 
allele (Table$2).
Prevalence of!Pfcrt K76T by!province
CQ resistance markers prevalence in Western Province 
was 2/122 [1.6% (0.2–5.7%)] while in Southern Province 
it was 1/29 [3.4% (0.08–17.2)] (Fig.$1). !e sample from 
Southern Province only contained the resistant allele, 
while the two from Western Province were mixed, i.e. 
containing a copy of both sensitive and resistant alleles. 
Figure$2 shows the district where these samples carrying 
resistant markers came from.
Discussion
Choloroquine (CQ) was a highly e"ective and cheap anti-
malarial whose utility was drastically reduced through 
the evolution of anti-malarial drug resistance. !is 
study reveals the return of CQ susceptible P. falciparum 
parasites in Southern and Western provinces of Zambia 
14$years following the withdrawal of chloroquine as first 
line treatment in 2003. In this study the overall geno-
typic prevalence of resistant parasites was 1.9%, with no 
di"erence between Southern (3.4%) and Western (1.6%) 
provinces. A total of 3 infections (1.9%) contained the 
resistant genotype, however two of these samples were 
also carrying a sensitive allele, suggesting that this allele 
has almost reached fixation in the population. In contrast, 
there were no Pfmdr N86Y resistant alleles observed in 
the study. !is mutation is a good indicator of treatment 
outcome as observed in a previous study where 68% of 
samples containing this mutation were associated with 
treatment failure [33].
!ese results mirror those observed in Northern Zam-
bia, Malawi and Kenya [21, 34–36]. In Zambia, while not 
linear, there has been a general reduction in the preva-
lence of the chloroquine resistance genotypes over time. 
From a high of 95% resistance in Macha in 2001 (unpub-
lished report as cited by Chileshe et$al. [33]). !is is seen 
from the gradual decrease observed from a multi-country 
study whose site in Zambia was from Ndola, Copperbelt 
province. It was conducted around 2004–2006 and 2006–
2007 and revealed that resistance was around 20–30% 
[37]. On the other hand, around the same period, samples 
collected from Lusaka revealed 54% in 2006–2007 [38]. 
A further reduction to 14.8% was observed from samples 
collected in Katete and Chipata (unpublished data) and 
0% in Nchelenge, Luapula Province, in 2012 [21]. Finally, 
2017 samples from Ndola, Copperbelt province identified 
zero resistance markers [39] (Fig.$3).
!e disappearance of CQ resistant parasites appears to 
be evolving at di"erent rates in the region probably due 
to co-varying factors such as treatments given; malaria 
transmission intensity (the rate of recombination among 
the parasites); and the use of related drugs like Amodi-
aquine capable of maintaining drug pressure on pfcrt 
[40]. Amodiaquine has never been used in Zambia, but it 
has been the second-line treatment for malaria in neigh-
bouring countries like Tanzania, whose nationals often 
travel to Zambia. As people travel from one place to 
another they import parasites [41]. In addition, infected 
Table 1 Demographic characteristics and!K76T mutations
Characteristics N % Pfcrt K76 (n) Mixed (n)
Sex
 Male 70 46.4 1 1
 Female 81 53.6 1
Age (years)
 < 5 25 16.6
 5–10 38 25.2 1
 11–15 22 14.6
 16–25 22 14.6
 26–40 18 11.8 1
 41–94 26 17.2 1
 Mean age (range) 20.8 (1–93 years)
Province
 Southern 31 20.0 1
 Western 124 80.0 2
Table 2 Prevalence of! Pfcrt76 and! Pfmdr 86 mutations 
in!Southern and!Western Provinces
Codon Resistant Mixed Sensitive
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Fig. 1 Prevalence of resistant and wild genes by Province
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individuals may carry resistant parasites; and these trav-
ellers could come with drugs from the neighbouring 
country that could alter the extent of drug pressure [42], 
these drugs could be shared with the Zambians they are 
visiting.
!is re-emergence of chloroquine sensitive P. falcipa-
rum parasites, also called ‘chemo-reversion’, is interpreted 
as a result of the absence of chloroquine drug pressure 
leading to the rapid re-expansion of susceptible parasites 
that had survived in some malaria semi-immune indi-
viduals in the population during that period of chloro-
quine use [34]. Furthermore, it has been suggested that 
the large-scale use of lumefantrine may have accelerated 
chemo-reversion by placing a selective pressure towards 
wild type Pfcrt alleles [40].
!is reduction of chloroquine resistant parasites could 
present a fresh chance to reintroduce chloroquine for 
malaria prevention especially in key vulnerable popula-
tions, as it is safe, well-tolerated in pregnancy at all stages 
and in children; and long-acting [21]. !is could replace 
sulfadoxine-pyrimethamine and should be introduced 
as a combination therapy with artesunate or with other 
short acting drugs to extend the useful lifespan of each 
of the drugs [43]. In light of the development of drug 
resistance, a short-term periodical alternate use of com-
binations with chloroquine may be used to reduce the 
development of resistance.
Study limitations
!ese results provide more information of the current 
state of pfcrtK76T allele in Western and Southern Prov-
inces of Zambia which will be referred to when discuss-
ing anti-malarial resistance in Zambia. However, these 
results should be interpreted with caution: first, the 
samples size for the low transmission area was small 
making comparison di#cult. !erefore, studies are 
required with a larger sample size that would provide 
more accurate estimates and comparisons of low and 
high transmission areas, especially after a long period 
of being low transmission areas in a place like Southern 
Province. Second, survey sampling in the two provinces 
was done di"erently making comparisons between 
the two more challenging. Finally, PCR bias cannot 
be ruled out completely as 26 samples did not amplify 
Fig. 2 Study districts in Southern and Western Province
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despite undergoing the pre-amplification process, this 
could have led to an under-or over-estimation of the 
prevalence.
Conclusion and!recommendation
!is study suggests CQ sensitive alleles dominate the 
genetic landscape in Southern (low transmission) and 
Western (high transmission) Provinces of Zambia 
14$ years after the withdrawal of CQ. Routine national 
surveillance of molecular resistant markers for anti-
malarial drugs should be included in the National 
Malaria Elimination Programmes as it strives for elimi-
nation. !is surveillance should be countrywide and 
samples from patients visiting health facilities should 
be included. Armed with this data, the programme can 
better understand the genetic challenges, and oppor-
tunities, for delivering prompt, e"ective treatment and 
chemo-protection.
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